A GAME CHANGER FORChronic wounds, cancer, inflammatory diseases & beyond

4-in-1 synthetic biology, cell and gene therapy platform

At Aurealis Therapeutics, we have built a unique multi-target cell and gene therapy platform to address unmet medical needs.

Discover the mode of action of our lead clinical asset AUP-16, a topical cell therapy that enables the healing of Diabetic Foot Ulcers (DFU) and other chronic, non-healing wounds.

Play Video

THE TEAM, THE SCIENCE & the outcome

Meet the TEAM

At Aurealis Therapeutics we are passionate about our science to make a difference for patients. Meet the Management Team, the Scientific Advisory Board, the Board of Directors, and the Aurealis Therapeutics Team Members.

Discover the SCIENCE

Our team takes pride in mastering the most advanced cell and gene therapy science, and making work in real life, from the lab to pre-clinical and to the clinic.

See the OUTCOME

Generating pre-clinical, clinical and health-economic evidence is how we want to make a difference. Seeing non-healing wounds healing, seeing how cancer deaths can be prevented – this is what matters the most.

Learn more About this
life-changing
technology

For Investors and Strategic Partners

Contact us

AUREALIS NEWS

Aurealis Therapeutics successfully completes treatment period of its Phase 1 study for AUP-16 in non-healing Diabetic Foot Ulcers: 83% patients receiving lead therapeutic dose achieved complete healing

Basel Switzerland, Kuopio Finland – June 14th, 2022.  Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that it has successfully completed its Phase 1 study of its lead therapeutic candidate AUP-16 in non-healing Diabetic Foot Ulcers patients, both in terms of patient recruitment and treatment. While patient observation […]

Read

Aurealis Therapeutics Publishes First Study on Four-in-One -Combination Therapy Using Live Lactococcus Lactis Expressing Three Human Therapeutic Proteins for the Treatment of Chronic Non-Healing Wounds

Basel Switzerland and Kuopio Finland– March 1st, 2022.  Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This […]

Read

Aurealis Therapeutics to Strengthen Its Management Team by Appointing Dr. Laurent Décory as Chief Operating Officer

Basel Switzerland and Kuopio Finland– February 25th, 2022. Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that Mr. Laurent Décory, who joined the Board of Directors in June 2020, has accepted to join the company management team as Chief Operating Officer. Laurent will be in charge of Business […]

Read